Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.:Journal of Clinical Oncology

Autor: Awada, Ahmad, Ochsenreither, Sebastian, Eefsen, Rikke Loevendahl, Arnold, Dirk, Yachnin, Jeffrey, Pfeiffer, Per, Jungels, Christiane, Greil, Richard, Poulsen, Laurids, Van Cutsem, Eric, Thorsson, Lars, Svedman, Christer, Garcia-Ribas, Ignacio, Collignon, Joelle

Publikováno v: Awada, A, Ochsenreither, S, Eefsen, R L, Arnold, D, Yachnin, J, Pfeiffer, P, Jungels, C, Greil, R, Poulsen, L, Van Cutsem, E, Thorsson, L, Svedman, C, Garcia-Ribas, I & Collignon, J 2021, ' Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. Journal of Clinical Oncology ', Journal of Clinical Oncology, vol. 39, no. Suppl. 15, e16228 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228
Awada, A, Ochsenreither, S, Eefsen, R L, Arnold, D, Yachnin, J, Pfeiffer, P, Jungels, C, Greil, R, Poulsen, L, Van Cutsem, E, Thorsson, L, Svedman, C, Garcia-Ribas, I & Collignon, J 2021, ' Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. Journal of Clinical Oncology ', Journal of Clinical Oncology, vol. 39, no. 15. suppl, e16228 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228

e16228Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in many solid tumors. CAN04 is a fully humanized IgG1 targeting IL1RAP blocking IL-1α and ? signaling and triggering ADCC. As monotherapy, C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7ca218eaa878e85447af075f89d15432
https://portal.findresearcher.sdu.dk/da/publications/92cc03ef-9e7d-4dec-bd62-d28a792af0f6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.